![]() |
|
|
Vol. 289, Issue 3, 1487-1491, June 1999
Department of Biopharmaceutical Sciences, University of California, San Francisco (M.E.S., J.W., L.Z., K.M.Ge., K.M.Gi.); and Department of Clinical Pharmacy, National Cheng Kung University, Tainan, Taiwan (S-F.S.)
| |
Abstract |
|---|
|
|
|---|
Nucleosides and nucleoside analogs are actively transported in the human kidney. With the recent cloning of a purine-selective, Na+-dependent, nucleoside transporter (hSPNT1, also termed hCNT2) from human kidney, it is now possible to study the interaction of nucleosides and nucleoside analogs with this transport protein and gain a more detailed knowledge of the underlying mechanisms of nucleoside transport in the human kidney. In this study we examined the substrate selectivity of hSPNT1 for nucleosides and nucleoside analogs. We determined that the naturally occurring nucleosides adenosine, inosine, and uridine are substrates for this carrier, whereas thymidine is not. The nucleoside analogs (0.5 mM) 2',3'-dideoxyadenosine; 2',3'-dideoxyinosine; and 2-chloro-2'deoxyadenosine (2CdA), significantly inhibited the uptake of [3H]inosine in HeLa cells transiently transfected with hSPNT1. However, there was no significant Na+-dependent uptake of [3H]2',3'-dideoxyinosine or [3H]2CdA in the transfected cells, suggesting that these nucleoside analogs are not permeants of hSPNT1. Interestingly, 2CdA was considerably less potent in inhibiting [3H]inosine uptake in HeLa cells expressing hSPNT1 than in cells expressing the rat homolog rSPNT (IC50 = 371 µM versus 13.8 µM), suggesting that there may be notable species differences in the kinetic interactions of some nucleoside analogs with purine- selective nucleoside transporters.
| |
Introduction |
|---|
|
|
|---|
By
selective reabsorption and secretion, transporters in the kidney play a
role in maintaining total body and tissue-specific homeostasis of
naturally occurring nucleosides (Griffiths et al., 1991
; Gutierrez et
al., 1992
; Gutierrez and Giacomini, 1993
; Ritzel et al., 1997
; Wang et
al., 1997
). These transporters may be particularly important in
regulating the local concentrations of nucleosides such as adenosine,
which have pronounced effects on renal function (Kuttesch and Nelson,
1982
; Thorn and Jarvis, 1996
). There have been limited studies
investigating the disposition of endogenous nucleosides in the human
kidney. Kuttesch and coworkers (Kuttesch and Nelson, 1982
; Nelson et
al., 1983
) observed that adenosine was reabsorbed, whereas the
2'-deoxynucleosides, 2-chloro-2'-deoxyadenosine (2CdA or cladribine)
and 2'-deoxyadenosine, were actively secreted in patients
lacking adenosine deaminase or treated with the deaminase inhibitor, deoxycoformycin.
With the cloning of several Na+-dependent
nucleoside transporters (Huang et al., 1994
; Che et al., 1995
; Ritzel
et al., 1997
; Wang et al., 1997
) it is now possible to understand the
molecular function of these carrier proteins. Recently, the cDNA
encoding a purine-selective, Na+-dependent
nucleoside transporter was cloned from human kidney in this laboratory
(Wang et al., 1997
). Northern blot analysis revealed a broad
distribution of multiple hSPNT1 transcripts, with expression in liver,
intestine, pancreas, heart, skeletal muscle, and in kidney (Wang et
al., 1997
). In contrast, mRNA transcripts of the rat homolog, rSPNT,
were not detected in rat kidney by Northern blotting methods (Che et
al., 1995
). These data suggest that there may be species differences in
the renal handling of purine nucleosides. Furthermore, it is not known
whether there are intrinsic differences in the functional
characteristics of the cloned human and rat purine-selective
transporters. This information is particularly important for
understanding the mechanisms involved in the renal transport of
nucleoside analogs, including the antiviral agent 2',3'-dideoxyinosine
(ddI) and the antineoplastic agent, 2CdA, with hSPNT1.
Mammalian expression systems have been used previously in this and
other laboratories to characterize the function of the cloned purine-
and pyrimidine-selective nucleoside transporters from rat (Fang et al.,
1996
; Schaner et al., 1997
). The goal of this study was to develop a
transiently transfected mammalian expression system for hSPNT1 and to
elucidate its functional characteristics and interactions with
nucleosides and nucleoside analogs. In particular, the role of hSPNT1
in the disposition of the endogenous nucleosides, inosine, uridine, and
adenosine, and various nucleoside analogs (e.g., 2'- 2CdA,
2'-deoxyadenosine, and ddI) was examined.
| |
Experimental Procedures |
|---|
|
|
|---|
HeLa cells were purchased from the American Type Culture Collection (ATCC, Manassas, VA). Minimum essential media, fetal bovine serum, penicillin-streptomycin, and fungizone were obtained from the University of California, San Francisco Cell Culture Facility. 2', 3'-Dideoxyadenosine (ddA); 2', 3'-dideoxycytidine (ddC); 2',3'-dideoxyinosine (ddI); uridine; thymidine; inosine; adenosine; guanosine; nitrobenzylthioinosine; 2CdA; 2'-deoxyadenosine; and acyclovir were purchased from Sigma Chemical Co. (St. Louis, MO). The DNA isolation kit was obtained from Qiagen (Santa Clarita, CA). The radioisotopes [3H]inosine [specific activity (S.A.), 27.8 Ci/mmol], [3H]uridine (S.A., 43.8 Ci/mmol), [3H]adenosine (S.A., 45.8 Ci/mmol), [3H]2'-deoxyadenosine (S.A., 27.8 Ci/mmol), [3H]2CdA (S.A., 3.8 Ci/mmol), and [3H]ddI (S.A., 38 Ci/mmol) were obtained from Moravek (Brea, CA). Lipofectamine and Opti-minimum essential media were supplied by Gibco/BRL (Gaithersburg, MD). Cell culture plates purchased from Nunc (Cambridge, MA) and 12-well plates purchased from Costar (Milpitas, CA) were used to maintain the cells and for uptake studies, respectively. The Bradford reagent for protein studies was purchased from Bio-Rad Labs. (Hercules, CA). The pcDNA3 vector was purchased from Invitrogen (Carlsbad, CA).
Methods
Transfection.
The cDNA encoding hSPNT1 was subcloned into
the pcDNA3 vector. Plasmid DNA was prepared using the Qiagen Maxi-prep
kit as previously described (Schaner et al., 1997
). An initial titering of the lipid demonstrated that significant expression of the
transporter was observed with DNA to lipid ratios between 1:4 and 1:6.
Maximal expression was observed at a ratio of 1:6 for the cDNA encoding hSPNT1; therefore this ratio was used for the study. HeLa cells were
seeded at a density of 2 × 105 cells/well
24 h before transfection. Transfection was carried out as
previously described (Schaner et al., 1997
). The efficiency of
transfection was not measured, but studies under identical transfection
conditions with a green fluorescent protein chimera of hSPNT1 suggest
that about 30 to 40% of the cells express the chimera hSPNT1 (from
confocal microscopy studies, data not shown).
Permeant Studies. Uptake studies were carried out 36 to 72 h after transfection. Uptake was measured in the presence of Na+ (128 mM NaCl, 4.73 mM KCl, 1.25 mM CaCl2, 1.25 mM MgSO4, and 5 mM HEPES, pH 7.4) or absence of Na+ (Na+ was replaced by 128 mM choline). The uptake was stopped by aspirating the reaction mixture and washing three times with ice-cold Na+-free buffer. Cells were then solubilized with 1 ml 0.5% Triton X-100 and 0.5 ml was sampled for liquid scintillation counting (Beckman Instruments, Palo Alto, CA).
For uptake studies with 3H nucleosides, a tracer amount of labeled compound was used (range 30-70 nM) plus 1 µM unlabeled compound. For [3H]2CdA, a concentration of 1.23 µM labeled plus 1 µM unlabeled compound was used. Protein concentrations were determined using the Bradford reagent, as described previously (Schaner et al., 1997Inhibition Studies. For inhibition studies, (a tracer concentration of labeled [3H]inosine (~70 nM plus 1 µM unlabeled inosine) was used as the permeant, and the amount of unlabeled compound used is indicated in the table or figure legends. In general, this concentration was 0.5 mM but varied in the IC50 studies. These experiments were carried out in duplicate or triplicate for 5 min. Data are presented as the mean ± S.D. Uptake assays were stopped as stated above. Inhibition studies were carried out in the presence and absence of Na+. As a control, Na+-dependent uptake was analyzed in cells transfected with empty vector.
Data Analysis. In general, data are expressed as mean ± S.D. of uptake values obtained in at least two to three wells. Data are representative of a minimum of two experiments carried out on different days. For Michaelis-Menten studies, rate of uptake was expressed as pmol/mg protein/5 min for inosine and pmol/mg protein/2 min for uridine. Data were fit to the equation V = Vmax[S]/(Km+[S]) where V is the rate of inosine or uridine uptake and [S] represents the concentration of inosine or uridine. The Kaleidagraph fitting program was used to fit the data. Parameter estimates are expressed as mean ± S.E. For IC50 studies, data were fit to the equation V = Vo/[1+(I/IC50)n] where V is the uptake of inosine in the presence of inhibitor, Vo is inosine uptake in the absence of inhibitor, I is the inhibitor concentration, and n is the Hill coefficient. An unpaired Student's t test from Primer of Biostatistics software (Version 3, by Stanton A. Glantz, McGraw-Hill, 1991) was used for determination of statistical significance, and P < .05 was considered statistically significant.
| |
Results |
|---|
|
|
|---|
In this study we demonstrated that hSPNT1 can be transiently
expressed in HeLa cells using the technique of lipofection. Similar techniques have been used previously in this laboratory to transiently transfect HeLa with the cDNA of the rat homolog, rSPNT (Schaner et al.,
1997
). The experimental conditions required for optimum expression of
hSPNT1 were essentially identical to those described for rSPNT except
that higher lipid to DNA ratios were used in this study (6:1 in
comparison with 3:1 used previously).
Uptake and Inhibition Studies.
The uptake of
[3H]inosine (~70 nM plus 1 µM
unlabeled inosine) in the presence of Na+ was
linear up to 30 min (data not shown) in HeLa cells transiently transfected with hSPNT1 cDNA. An initial time point of 5 min was used
for further kinetic studies. At 0.5 mM, the purine nucleosides, adenosine, guanosine, and inosine, significantly inhibited
Na+-dependent [3H]inosine
uptake, whereas the pyrimidine nucleosides, thymidine and cytidine, did
not (Fig. 1). The pyrimidine nucleoside,
uridine, which is a substrate of all known mammalian nucleoside
transporters (Crawford et al., 1990
; Crawford and Belt, 1991
;
Plagemann, 1991
; Ritzel et al., 1997
), also significantly inhibited
[3H]inosine uptake (P < .05).
|
|
|
Permeant Studies.
Although inhibition studies do show
interaction with the carrier, such studies do not necessarily
identify substrates (or permeants) of the transporter. To
identify other substrates of hSPNT1, the uptake of several
3H-labeled nucleosides and nucleoside analogs was
determined in HeLa cells transiently transfected with the cDNA of
hSPNT1. Uptake of [3H]inosine,
[3H]uridine,
[3H]thymidine,
[3H]adenosine,
[3H]2'-deoxyadenosine,
[3H]2CdA, and [3H]ddI
was measured for 5 min in the presence and absence of
Na+ in HeLa cells transiently transfected with
hSPNT1 cDNA. [3H]Inosine and
[3H]uridine demonstrated significant
(P < .05) uptake by this carrier, whereas
[3H]ddI and
[3H]thymidine did not (Fig.
3). [3H]Adenosine
showed significant Na+-dependent uptake in the
cells expressing hSPNT1, whereas
[3H]2'-deoxyadenosine and
[3H]2CdA did not (Fig.
4). Similar results were also obtained
when uptake was carried out at 1 min (data not shown). The kinetics of
uridine and inosine uptake were further characterized. In this study a
time point of 2 min was used for uridine, because uridine uptake was
linear up to this time point but was not linear at 5 min. Both
compounds demonstrated saturable uptake in the transfected cells (Table
2); however, in comparison to the
interaction of inosine (Km = 13.7 ± 8.09 µM; Vmax = 182 ± 40 pmol/mg protein/5 min), the interaction of uridine was characterized by
a lower affinity and higher capacity
(Km = 116 ± 26 µM;
Vmax = 728 ± 98 pmol/mg
protein/2 min). The Na+-dependent uptake of
[3H]adenosine (1 µM) was significantly higher
in HeLa cells transfected with the cDNA encoding rSPNT versus cells
transfected with the cDNA encoding hSPNT1 (Fig.
5).
|
|
|
|
| |
Discussion |
|---|
|
|
|---|
The kidney plays a vital role in maintaining total body and local purine homeostasis. Limited data suggest that 2'-deoxyribonucleosides are handled differently from ribonucleosides by the human kidney. Namely, 2'-deoxyadenosine and 2CdA are both actively secreted, whereas adenosine is actively reabsorbed. Previously, we demonstrated that both adenosine and 2'-deoxyadenosine inhibit [3H]inosine uptake in Xenopus laevis oocytes expressing hSPNT1; however, the IC50 of adenosine was lower than that of 2'-deoxyadenosine (23 µM versus 110 µM). In this study, we addressed the question of whether adenosine and 2'-deoxyadenosine are permeants of hSPNT1. Our data demonstrate that adenosine is a permeant of hSPNT1, whereas neither 2'-deoxyadenosine nor 2CdA showed significant uptake by the transporter (Fig. 4). However, both compounds showed a slight, albeit not significant, Na+-dependent uptake, suggesting that these compounds may be poor permeants of hSPNT1. Collectively, the data suggest that hSPNT1 may play a role in the reabsorption of adenosine in the human kidney but does not appear to play a role in the secretion of either 2'-deoxyadenosine or 2CdA. Understanding the sorting of hSPNT1 to the apical or basolateral membrane of the proximal tubule will provide further information on the physiological role of the transporter.
In this study, the Km of uridine for
hSPNT1 (116 µM) was similar to the value obtained previously in this
laboratory in the X. laevis oocyte expression system (80 µM, Table 3). These values are somewhat
higher than the Km of uridine (45 µM) in interacting with the human pyrimidine-selective transporter,
hCNT1(Ritzel et al., 1997
), suggesting that although both hSPNT and
hCNT1 transport uridine, the pyrimidine-selective transporter has a
higher affinity for uridine. Both transporters may play a role in the
transport of uridine (as well as adenosine) in the human kidney.
|
Similar to 2'-deoxyadenosine and 2CdA, the antiviral nucleoside analog, ddI, is actively secreted in the human kidney. Our data demonstrate that ddI is a potent inhibitor (IC50 of 19 µM) of [3H]inosine uptake in HeLa cells expressing hSPNT1; however, ddI is not a permeant. These data suggest that hSPNT1 does not contribute to the secretory clearance of either dideoxy or 2'-deoxynucleosides.
Our results demonstrate possible species differences between the human
transporter and that cloned from rat (Table 3). The IC50 of 2CdA (371 µM) in inhibiting
[3H]inosine uptake in cells expressing hSPNT1
was markedly different from the IC50 of 2CdA
(13.7 µM) in cells expressing rSPNT. Furthermore, consistent with
previous studies in X. laevis oocytes, the uptake of
[3H]2CdA in hSPNT1 cDNA transfected cells was
only slightly enhanced. In contrast, in HeLa cells transfected with the
cDNA of rSPNT Na+-dependent uptake of
[3H]2CdA was enhanced more than 2-fold over
that in the absence of Na+ (Schaner, 1997
).
Because 2CdA is an antineoplastic agent with numerous clinical
applications (Saven et al., 1995
, 1996
; Pott and Hiddemann, 1997
; Stine
et al.,1997
; Tobinai et al., 1997
), a knowledge of species differences
in the interaction of this compound and other 2'-deoxynucleoside
analogs with the purine-selective nucleoside transporters may be
significant for future evaluation of these compounds in animal models.
Adenosine (1 µM) exhibits a higher rate of uptake in cells expressing
rSPNT in comparison with those expressing hSPNT1. This higher uptake
rate may be due to differences in the
Km of adenosine in interacting with
the rat and human transporters; alternatively, the expression level of
rSPNT may be greater than that of hSPNT1. The species differences
observed for both adenosine and 2CdA in interacting with hSPNT1 and
rSPNT may be due to differences in the molecular structures of the two
clones. A recent study from this laboratory (Wang and Giacomini, 1997
)
examined the molecular basis for substrate selectivity using the
purine- and pyrimidine-selective rat clones. Similar studies between
hSPNT1 and rSPNT may elucidate important species differences.
Interestingly, rSPNT is not expressed (to a significant extent) in rat
kidney (Che et al., 1995
; our unpublished data). This may suggest an
important difference in the renal handling of purine nucleosides
between species, which must be considered when evaluating such
compounds in animal models.
In summary, the human purine-selective, Na+-dependent transporter (hSPNT1) was expressed in HeLa cells. The characteristics of hSPNT1 in interacting with a number of nucleosides and nucleoside analogs were determined. Notable species differences in the function of hSPNT1 when compared with the rat homolog, rSPNT, were observed. These results suggest that caution should be taken when evaluating purine nucleosides and nucleoside analogs in the rat. The underlying molecular mechanisms that contribute to such species differences remain to be elucidated. Transient transfection of the cDNA encoding hSPNT1 in HeLa cells represents a useful model to further characterize the interactions of nucleosides and nucleoside analogs with the transporter.
| |
Footnotes |
|---|
Accepted for publication January 28, 1999.
Received for publication May 11, 1998.
1 This work was supported by National Institutes of Health Grant GM42230.
Send reprint requests to: Kathleen M Giacomini, Ph.D., Schools of Pharmacy and Medicine, Departments of Biopharmaceutical Sciences and Cellular and Molecular Pharmacology, 513 Parnassus, Box 0446, S-926, University of California, San Francisco, San Francisco, CA 94143-1936. E-mail: kmg{at}itsa.ucsf.edu
| |
Abbreviations |
|---|
ddA, 2', 3'-dideoxyadenosine; ddC, 2', 3'-dideoxycytidine; ddI, 2',3'-dideoxyinosine; 2CdA, 2-chloro-2'deoxyadenosine.
| |
References |
|---|
|
|
|---|
This article has been cited by other articles:
![]() |
L. Guida, S. Bruzzone, L. Sturla, L. Franco, E. Zocchi, and A. De Flora Equilibrative and Concentrative Nucleoside Transporters Mediate Influx of Extracellular Cyclic ADP-Ribose into 3T3 Murine Fibroblasts J. Biol. Chem., November 27, 2002; 277(49): 47097 - 47105. [Abstract] [Full Text] [PDF] |
||||
![]() |
Y. Lai, A. H. Bakken, and J. D. Unadkat Simultaneous Expression of hCNT1-CFP and hENT1-YFP in Madin-Darby Canine Kidney Cells. LOCALIZATION AND VECTORIAL TRANSPORT STUDIES J. Biol. Chem., September 27, 2002; 277(40): 37711 - 37717. [Abstract] [Full Text] [PDF] |
||||
![]() |
K. M. Gerstin, M. J. Dresser, and K. M. Giacomini Specificity of human and rat orthologs of the concentrative nucleoside transporter, SPNT Am J Physiol Renal Physiol, August 1, 2002; 283(2): F344 - F349. [Abstract] [Full Text] [PDF] |
||||
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||